Director-led Australian regulatory support for gene therapy, genetically modified cell therapy and other advanced-therapy programmes — from early pathway assessment and OGTR planning through application support and coordination with TGA, HREC, IBC and clinical-trial start-up requirements.
Australian programmes involving gene technology can involve obligations beyond the standard clinical-trial pathway. OGTR requirements may sit alongside TGA, HREC, institutional, site and sponsor requirements, and the right sequence depends on the product and the proposed Australian dealings.
Not every cell or advanced therapy is a GMO dealing. Early, product-specific assessment helps sponsors distinguish what applies now, what may be changing and where responsibilities need to be allocated before trial start-up assumptions become fixed.
Tricode helps sponsors develop a defensible Australian regulatory position without treating pathway classification as automatic before the relevant programme information is available.
Review the product, vector, genetic modification, proposed dealings and Australian activities against the Gene Technology Act framework.
Translate the assessment into a practical regulatory sequence aligned with the sponsor’s development plan and Australian start-up model.
Where an OGTR licence or other authorisation is required, Tricode can support application strategy, preparation or review, supporting-document coordination, regulatory gap identification, communications and responses to information requests.
Tricode provides regulatory leadership and coordination while working with appropriately qualified scientific, biosafety, manufacturing and technical contributors where their specialist input is required.
Gene-technology requirements should not be treated as an isolated late-stage task. The Australian workstream may involve OGTR, an Institutional Biosafety Committee, TGA clinical-trial requirements, HREC review, institutional governance, site operations and Australian sponsor responsibilities.
Tricode helps create alignment across those interfaces, with clear ownership of the work that sits within the agreed scope.
Where IBC review is required, Tricode can coordinate the process and, where appropriate, facilitate access to commercial IBC support as part of the broader Australian regulatory workstream. Tricode does not act as the IBC.
Tricode supports regulatory planning for gene therapies, genetically modified cell therapies, viral-vector programmes, relevant biologicals and other advanced therapies where OGTR and TGA considerations may intersect.
Not every advanced therapy is regulated under the Gene Technology Act. The Australian analysis depends on whether the product or proposed activity involves a GMO and on the nature of the dealings involved. That distinction is important for both regulatory accuracy and efficient programme planning.
Global development assumptions do not automatically determine the Australian pathway. Tricode can translate the programme into Australian requirements, identify OGTR obligations early, align activities with global timelines and clarify local regulatory responsibilities.
Tricode can act as the lead Australian regulatory adviser for an agreed scope or work alongside existing sponsor teams, CROs, sites and other specialist providers. Where clinical-trial start-up is also in scope, see Clinical Trial Regulatory Support.
Engagements are shaped around the sponsor’s actual gap, with clear ownership and practical sequencing.
Review the product, technology, proposed dealings and Australian activities.
Establish relevant OGTR, TGA, HREC, IBC and institutional interfaces.
Prepare or review materials, coordinate information and assign responsibilities.
Support questions, amendments, additional sites and ongoing requirements within scope.
Clients work directly with Tricode Clinical’s Director throughout the engagement.
Practical experience across Australian clinical development, TGA requirements, OGTR-regulated trials and IBC processes.
OGTR considerations are assessed alongside clinical-trial, ethics, sponsor and development requirements.
Tricode can provide strategic advice, lead a defined workstream or integrate with an existing sponsor and CRO structure.
The proposed reforms may introduce new GMO Permit and non-notifiable pathways relevant to some therapeutic GMO and genetically modified cell-therapy programmes, while the current framework remains in force.
Read the Regulatory Insight →Regulatory information on this page was reviewed on 26 August 2026. Requirements should be confirmed for the specific product and programme before implementation.
Discuss pathway assessment, OGTR requirements, Australian trial planning, regulatory sequencing or a defined Australian regulatory workstream.
Discuss Your Australian Programme